$21M Compounding Pharmacy Exposes Why Peptides are Trending | Ep. 407 with Kris Fishman CEO and President of Wells Pharmacy Network

Episode notes

Daniel and Kris Fishman explore why compounding pharmacies are suddenly part of the national health conversation, especially as GLP-1s, peptides, and personalized medicine become mainstream. Kris breaks down what compounding actually means, why “one size fits all” medicine is being questioned, and how pharmacies like Wells step in when traditional options are unavailable or not personalized enough. The conversation also covers FDA scrutiny, peptide regulation, Big Pharma tension, operational scale, and the emotional reality of leading a fast-growing healthcare company. Key Discussion Points Kris explains that compounding pharmacies go back centuries and combine active pharmaceutical ingredients to create personalized preparations when standard retail versions do not fit a patient’s needs. He breaks down why peptides became a major health trend, describing them as amino acid chains that have gained traction through wellness culture, social media, and gray-market demand. Kris discusses the FDA’s review process and the importance of the upcoming PCAC meeting, where physicians and pharmacists can explain why certain peptides should be available for compounding.